|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
27
|
|
pubmed:dateCreated |
2001-6-7
|
|
pubmed:abstractText |
Human papillomavirus (HPV) E6 and E7 oncoproteins are attractive targets for T-cell-based immunotherapy of cervical intraepithelial neoplasia (CIN) and cancer. A newly designed vaccine, comprising the HPV16 L2, E6 and E7 as a single fusion protein (TA-CIN), was shown to elicit HPV16-specific CTL, T-helper cells and antibodies in a pre-clinical mouse model. These immune responses effectively prevented outgrowth of HPV16-positive tumour cells in a prophylactic setting as well as in a minimal residual disease setting. CTL immunity was optimally induced when TA-CIN was employed in heterologous prime-boost regimens in combination with TA-HPV, a clinical grade vaccinia-based vaccine. These data provide a scientific basis for the use of TA-CIN, alone or in combination with TA-HPV in future human trials.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Capsid Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/L2 protein, Human papillomavirus...,
http://linkedlifedata.com/resource/pubmed/chemical/Oncogene Proteins, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Papillomavirus E7 Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Acellular,
http://linkedlifedata.com/resource/pubmed/chemical/oncogene protein E7, Human...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0264-410X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
14
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3652-60
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11395199-Animals,
pubmed-meshheading:11395199-Antigens, Neoplasm,
pubmed-meshheading:11395199-Antigens, Viral,
pubmed-meshheading:11395199-Cancer Vaccines,
pubmed-meshheading:11395199-Capsid,
pubmed-meshheading:11395199-Capsid Proteins,
pubmed-meshheading:11395199-Cell Line,
pubmed-meshheading:11395199-Cell Line, Transformed,
pubmed-meshheading:11395199-Cervical Intraepithelial Neoplasia,
pubmed-meshheading:11395199-Drug Evaluation, Preclinical,
pubmed-meshheading:11395199-Immunotherapy,
pubmed-meshheading:11395199-Mice,
pubmed-meshheading:11395199-Mice, Inbred C57BL,
pubmed-meshheading:11395199-Oncogene Proteins, Viral,
pubmed-meshheading:11395199-Papillomaviridae,
pubmed-meshheading:11395199-Papillomavirus E7 Proteins,
pubmed-meshheading:11395199-Recombinant Fusion Proteins,
pubmed-meshheading:11395199-Vaccines, Acellular
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens.
|
|
pubmed:affiliation |
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Building 1, E3-Q, PO Box 9600, 2300 RC Leiden, The Netherlands. shvdburg@worldonline.nl
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
